ADPT (Adaptive Biotechnologies) Moat Score: 5/10 (As of Jun. 29, 2026)


ADPT Adaptive Biotechnologies Corp ADPT
67 GF Score
Price $21.46
GF Value $10.06
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Adaptive Biotechnologies Moat Score?

Adaptive Biotechnologies ADPT +2.36% 67 Moat Score is 5 as of Jun. 29, 2026. GuruFocus rates ADPT with a GF Score™ of 67/100 and a GF Value™ of $10.06 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 216 Medical Diagnostics & Research companies, Adaptive Biotechnologies ranks better than 87.5% on this metric.

Adaptive Biotechnologies has the Moat Score of 5, which implies that the company might have Narrow Moat - Solid narrow moat.

Adaptive Biotechnologies has Narrow Moat: Adaptive Biotechnologies Corp has a solid narrow moat due to its valuable intellectual property and innovation in biotechnology. However, it lacks strong brand strength and significant customer switching costs, limiting its competitive position.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Adaptive Biotechnologies might have Narrow Moat - Solid narrow moat.

Adaptive Biotechnologies  (NAS:ADPT) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Adaptive Biotechnologies Moat Score Related Terms

ADPT vs GRAL, WGS, RDNT: Moat Score Comparison

For the Diagnostics & Research subindustry, Adaptive Biotechnologies's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Adaptive Biotechnologies Moat Score vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Adaptive Biotechnologies's Moat Score distribution charts can be found below:

* The bar in red indicates where Adaptive Biotechnologies's Moat Score falls into.


ADPT
67GF Score
Adaptive Biotechnologies Corp ADPT
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 5 mean?
Adaptive Biotechnologies (ADPT) has a Moat Score of 5 as of Jun. 29, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Adaptive Biotechnologies ranks #27 out of 216 companies in the Medical Diagnostics & Research industry, placing it in the top 12.5%.
Is Adaptive Biotechnologies' Moat Score too high?
Adaptive Biotechnologies' current Moat Score is 5. Based on the distribution chart, Adaptive Biotechnologies ranks #27 out of 216 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Adaptive Biotechnologies has a GF Score™ of 67/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Adaptive Biotechnologies' Moat Score compare to GRAL and WGS?
According to the Medical Diagnostics & Research industry distribution chart, Adaptive Biotechnologies ranks #27 out of 216 companies for Moat Score. This places Adaptive Biotechnologies in the top 13% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Medical Diagnostics & Research company?
A good Moat Score depends on the Medical Diagnostics & Research industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Adaptive Biotechnologies's current Moat Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adaptive Biotechnologies stock overvalued right now?
Based on GuruFocus' analysis, Adaptive Biotechnologies (ADPT) is currently considered Significantly Overvalued. The stock's GF Value™ is $10.06, compared to a current price of $21.46 — trading 113.3% above its estimated fair value. The current Moat Score is 5. Adaptive Biotechnologies' overall GF Score™ is 67/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Adaptive Biotechnologies (ADPT), the current Moat Score is 5 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Adaptive Biotechnologies (ADPT) Overvalued in 2026?

Based on GuruFocus' analysis, Adaptive Biotechnologies stock appears to be overvalued. The current stock price of $21.46 is trading 113.3% above its estimated GF Value™ of $10.06. GuruFocus considers Adaptive Biotechnologies to be Significantly Overvalued.

Key valuation signals for ADPT:

  • Moat Score: 5
  • GF Value™: $10.06 vs. price of $21.46 (113.3% above fair value)
  • GF Score™: 67/100 with 5 warning signs

No single metric tells the full story. See the ADPT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Adaptive Biotechnologies Business Description

Other Exchanges 1HM:Germany
Address 1165 Eastlake Avenue East, Seattle, WA, USA, 98109
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.
67GF Score

Get the complete analysis for ADPT

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$21.46
Price
$10.06
GF Value